Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin

Insider Monkey10-16

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475910554?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mlJjdy0U1hSdvI3yTxDWOQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/52f642755a03dba96aec7e2253ee8ac5","is_english":true,"pubTime":"2024-10-16 20:44","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2475910554","market":"us","top_or_hot":-1,"title":"Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin","media":"Insider Monkey","content":"<div>\n<p>We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest ...</p>\n\n<a href=\"https://finance.yahoo.com/news/akero-therapeutics-akro-leading-charge-124443853.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-16 20:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/akero-therapeutics-akro-leading-charge-124443853.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest ...</p>\n\n<a href=\"https://finance.yahoo.com/news/akero-therapeutics-akro-leading-charge-124443853.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".IXIC","symbol_name":"NASDAQ Composite","start_time":0,"source_url":"https://finance.yahoo.com/news/akero-therapeutics-akro-leading-charge-124443853.html","article_id":"2475910554","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mlJjdy0U1hSdvI3yTxDWOQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/52f642755a03dba96aec7e2253ee8ac5"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475910554","pubTimestamp":1729082683,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’  stands against other biggest stocks with negative beta to consider.Beta is a measureament of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and down compared to other stocks. It is a statistical measure that helps investors understand the risk associated with a particular stock. Beta is calculated using regression analysis, a set of statistical methods used for the estimation of relationships between one or more independent variables, and is represented by the Greek letter ‘’. Beta gives a sense of the stock’s risk compared to that of the greater market.Tom Lee, Managing Partner and Head of Research at Fundstrat Global Advisors shared his market insights in an interview on CNBC on October","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{".IXIC":"NASDAQ Composite","BK4139":"生物科技","BK4588":"碎股","QID":"纳指两倍做空ETF","EFX":"艾可菲","BK4123":"调查和咨询服务","PSQ":"纳指反向ETF","TQQQ":"纳指三倍做多ETF","AKRO":"Akero Therapeutics","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓"},"translate_title":"Akero Therapeutics(AKRO)：在Efruxifermin治疗MASH方面处于领先地位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1,"EFX":1,".IXIC":0.9,"US7Y.BOND":0.9,"US6M.BOND":0.9,"US5Y.BOND":0.9,"US3Y.BOND":0.9,"US30Y.BOND":0.9,"US2Y.BOND":0.9,"US12M.BOND":0.9,"US10Y.BOND":0.9,"US912797HE00.BOND":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Akero Therapeutics’ (NASDAQ:AKRO) stands against other biggest stocks with negative beta to consider.\nBeta is a measureament of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and down compared to other stocks. It is a statistical measure that helps investors understand the risk associated with a particular stock. Beta is calculated using regression analysis, a set of statistical methods used for the estimation of relationships between one or more independent variables, and is represented by the Greek letter ‘ß’. Beta gives a sense of the stock’s risk compared to that of the greater market.\nA beta of 1 indicates that the security’s price tends to move with the market. A beta greater than 1 indicates that the security’s price is more volatile than the market. A beta of less than 1 means it tends to be less volatile than the market. For example, if a company has a beta of 2, it means that it is two times as volatile as the overall market.\nBenefits of Investing in Negative Beta Stocks\nA negative beta is a rare occurrence, but it indicates an inverse relationship between the stock’s price and the market. In other words, when the market declines, the stock’s price tends to rise, and when the market rises, the stock’s price tends to fall. A negative beta is highly unlikely, but it can occur in certain situations. For example, some investors argue that gold and gold stocks should have negative betas because they tend to do better when the stock market declines. This is because gold is often seen as a safe-haven asset, and investors tend to flock to it during times of market uncertainty.\nIn more detail, a negative beta means that the stock’s price is negatively correlated with the market. This means that when the market rises, the stock’s price tends to fall, and when the market falls, the stock’s price tends to rise. This can be beneficial for investors who are looking to diversify their portfolios and reduce their overall risk. However, it’s worth noting that a negative beta is not always a guarantee of success, and investors should still do their due diligence before investing in any stock.\nWhile negative betas are rare, there are some examples of stocks that have exhibited negative beta characteristics. For example, during the 2008 financial crisis, the price of gold rose significantly while the stock market declined. This is an example of a negative beta, where the price of gold moved in the opposite direction of the market. Similarly, some defensive stocks like consumer staples and healthcare stocks tend to have negative betas because they are less affected by market fluctuations.\nTom Lee Expects Market Rally to Continue After Election\nTom Lee, Managing Partner and Head of Research at Fundstrat Global Advisors shared his market insights in an interview on CNBC on October 12, as the S&P 500 reached a new high, breaking above 5,800 for the first time ever. Despite the current bull run, which marks its two-year anniversary, Lee expressed caution about the market as the month progresses.\nLee advised his clients to “buy the dips” but thinks investors are waiting for the outcome of the presidential election before making major moves. He believes that once the election is over, the market will rally, with a target of around 6,000 for the S&P 500.\nAccording to Lee, there are several factors supporting a potential market rally. Firstly, the Federal Reserve is taking a dovish stance, which is expected to continue supporting the market. Secondly, the economy looks healthy, and Lee does not think a recession is on the horizon.\nLee also pointed out that investors who have been cautious for the past two years are starting to realize that the $6 trillion in cash on the sidelines and the low levels of margin debt need to be put to work at a time when the Fed is supporting the market.\nHowever, Lee acknowledged potential headwinds that could impact the market. One of the concerns is valuation, with the S&P 500 trading at a price-to-earnings (P/E) ratio of around 21.5, which is above its historical average. Some investors may view this as a sign that the market is overvalued.\nAnother concern is the rise in yields, which could make bonds more attractive to investors and potentially draw money away from the stock market. Although Lee noted that yields are up for the right reasons, as the economy is growing, he acknowledged that they are still higher than expected after the Fed’s 50-basis-point rate cut.\nFinally, Lee addressed the possibility of slower and smaller rate cuts from the Fed, which could impact the market. However, he believes that the Fed’s goal is to normalize interest rates back towards neutral, as inflation pressures are ebbing. Lee thinks that this is a positive development, as it suggests that the Fed is confident in the economy’s resilience.\nBeta is a useful measure of a stock’s volatility and risk. A negative beta indicates an inverse relationship between the stock’s price and the market, which can be beneficial for investors looking to diversify their portfolios.\nOur Methodology\nTo compile our list of the 10 biggest stocks with negative beta to consider, we used the Finviz and Yahoo stock screeners to find the largest companies with a beta of less than zero. We then narrowed our choices to 10 stocks according to their hedge fund sentiment, which was taken from our database of 912 elite hedge funds as of Q2 of 2024. The list is sorted in ascending order of their hedge fund sentiment, as of the second quarter.\nWhy do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\n A busy convenience store with customers stocking up on fuel and merchandise. \nAkero Therapeutics (NASDAQ:AKRO)  \nNumber of Hedge Fund Investors: 31  \nBeta: -0.25  \nMarket Cap as of October 13: $2.06 Billion\nAkero Therapeutics (NASDAQ:AKRO) is a biotechnology company that is developing a treatment for Metabolic dysfunction-Associated Steatohepatitis (MASH), a condition characterized by the accumulation of fat in the liver. The company’s lead candidate, Efruxifermin (EFX), is an FGF21 analog that has shown strong results in pre-cirrhotic MASH.\nMASH is a condition that affects an estimated 250 million people worldwide and is characterized by the accumulation of fat in the liver, inflammation, and fibrosis. The market potential for MASH treatments is estimated to be over $25 billion by 2032.\nThe MASH market is highly competitive, with many pipeline drugs and one approved drug, resmetirom. Resmetirom, is an oral, liver-directed, thyroid hormone receptor that has been approved for the treatment of NASH with liver fibrosis.\nAkero Therapeutics’ (NASDAQ:AKRO) EFX has shown strong results in pre-cirrhotic MASH, with a 63-72% relative reduction in liver fat and a 24-32 U/L reduction in the liver enzyme ALT. However, in the SYMMETRY trial, only 22% to 24% of patients in the drug arm showed at least one stage improvement in fibrosis with no worsening of NASH at week 36.\nAkero Therapeutics’ (NASDAQ:AKRO) has a cash balance of $848 million. Research and development expenses for the three-month period ended June 30, were $55.3 million, while general and administrative expenses were $10.4 million. At that rate, the company has a cash runway well into 2027, or beyond its expected date of data drop from the ongoing phase 3 trial.\nAkero Therapeutics’ (NASDAQ:AKRO) is a good candidate for a basket of MASH players. The company’s EFX has differentiated itself well in pre-cirrhotic MASH, and the 96-week data may change the outcome in cirrhotic MASH. With a consensus Buy rating from industry analysts, Akero Therapeutics’ (NASDAQ:AKRO) stock has a target price of $45.78, which represents a 42.83% upside potential from its current level.\nOverall, AKRO ranks 7th on our list of biggest stocks with negative beta to consider. While we acknowledge the potential of AKRO to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than AKRO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.\nREAD NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.\nDisclosure: None. This article is originally published at Insider Monkey.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475910554"}